



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:27
Last Report Issued 08/24/2015 10:41

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 4261SP
Patient ID 4261SP
Chain 15001009
Age Not Given DOB Not Given
Gender Not Given
Workorder 15001009
Received 05/12/2015 08:57

Sample ID 15001009-001
Matrix Serum or Plasma
Patient Name 4261SP
Patient ID 4261SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Rosiglitazone, Chlorpropamide, Tolbutamide, and Tolazamide.

Results for sample 15001009-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 15001009-001
Matrix Serum or Plasma
Patient Name 4261SP
Patient ID 4261SP

Collect Dt/Tm Not Given
Source Not Given

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes. Rows include Tolinase, Glipizide, Pioglitazone, Glyburide, Glimpiride, Nateglinide, and Repaglinide.

Results for sample 15001009-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 15001009-001
Matrix Serum or Plasma
Patient Name 4261SP
Patient ID 4261SP

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

Synonym(s): Prandin®; PrandiMet®

Peak plasma concentrations of approximately <10 - 180 ng/mL were achieved 1 hour after administration of 4 mg of repaglinide.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.